Potential Therapeutic Interactions of CMTM8 in Neurological Disorders
Potential Therapeutic Interactions of CMTM8 in Neurological Disorders
CMTM8, also known as CMTM8 variant 1, is a protein that is expressed in the brain and has been shown to play a role in various neurological conditions, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. The protein is composed of four domains: a N-terminus, a T-terminus, a middle alpha-helix, and a C-terminus. It is approximately 40 amino acids long and has a pI of approximately 9.0.
CMTM8 has been shown to interact with various protein partners, including beta-amyloid, tau, and p53. It has also been shown to play a role in the regulation of neurotransmitter release and cell survival.
One of the most promising aspects of CMTM8 is its potential as a drug target. Studies have shown that CMTM8 can be targeted by small molecules, including those that inhibit its interaction with beta-amyloid and tau. Additionally, CMTM8 has been shown to play a role in the regulation of neurotransmitter release, which could make it an attractive target for drugs that target neurotransmitter release.
Another potential use of CMTM8 is as a biomarker for various neurological conditions. The protein is expressed in the brain and has been shown to be involved in the regulation of neurotransmitter release, which could make it an attractive target for biomarkers that reflect neurotransmitter release. This could be useful for the diagnosis and treatment of neurological conditions, such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
In conclusion, CMTM8 is a protein that has been shown to play a role in various neurological conditions, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. It is also a potential drug target and biomarker. Further research is needed to fully understand its role in the regulation of neurotransmitter release and its potential as a drug and biomarker.
Protein Name: CKLF Like MARVEL Transmembrane Domain Containing 8
More Common Targets
CMTR1 | CMTR2 | CMYA5 | CNBD1 | CNBD2 | CNBP | CNDP1 | CNDP2 | CNE9 | CNEP1R1 | CNFN | CNGA1 | CNGA2 | CNGA3 | CNGA4 | CNGB1 | CNGB3 | CNIH2 | CNIH3 | CNIH4 | CNKSR1 | CNKSR2 | CNKSR3 | CNMD | CNN1 | CNN2 | CNN2P2 | CNN2P4 | CNN3 | CNN3-DT | CNNM1 | CNNM2 | CNNM3 | CNNM4 | CNOT1 | CNOT10 | CNOT11 | CNOT2 | CNOT3 | CNOT4 | CNOT4P1 | CNOT6 | CNOT6L | CNOT6LP1 | CNOT7 | CNOT8 | CNOT9 | CNP | CNPPD1 | CNPY1 | CNPY2 | CNPY3 | CNPY4 | CNR1 | CNR2 | CNRIP1 | CNST | CNTD1 | CNTF | CNTFR | CNTLN | CNTN1 | CNTN2 | CNTN3 | CNTN4 | CNTN4-AS1 | CNTN4-AS2 | CNTN5 | CNTN6 | CNTNAP1 | CNTNAP2 | CNTNAP2-AS1 | CNTNAP3 | CNTNAP3B | CNTNAP3P2 | CNTNAP4 | CNTNAP5 | CNTRL | CNTROB | COA1 | COA3 | COA4 | COA5 | COA6 | COA6-AS1 | COA7 | COA8 | Coagulation Factor XIII | COASY | Coatomer protein complex | COBL | COBLL1 | COCH | COG1 | COG2 | COG3 | COG4 | COG5 | COG6 | COG7